Does Rallies show Form 4 insider transactions for INSM?

Yes. Rallies tracks INSM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is INSM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for INSM. It does not provide personalized investment advice.

INSM (Insmed) Stock Analysis - Insider Trades

Insmed (INSM) is a publicly traded Healthcare sector company. As of May 20, 2026, INSM trades at $107.56 with a market cap of $23.23B and a P/E ratio of -18.64. INSM moved +0.37% today. Year to date, INSM is -38.41%; over the trailing twelve months it is +57.51%. Its 52-week range spans $60.40 to $212.75. Analyst consensus is strong buy with an average price target of $203.20. Rallies surfaces INSM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading INSM stock inside the company?

Recent INSM insider activity includes Flammer Martina M.D. sold 10.48K, Bonstein Sara sold 8.27K, Adsett Roger sold 5.84K, Flammer Martina M.D. sold 4.47K, and Flammer Martina M.D. sold 3.38K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

INSM Key Metrics

Key financial metrics for INSM
Metric	Value
Price	$107.56
Market Cap	$23.23B
P/E Ratio	-18.64
EPS	$-5.74
Dividend Yield	0.00%
52-Week High	$212.75
52-Week Low	$60.40
Volume	2.61M
Avg Volume	0
Revenue (TTM)	$819.56M
Net Income	$-1.18B
Gross Margin	81.81%

Recent INSM Insider Trades

Flammer Martina M.D. sold 10.48K (~$1.23M) on May 14, 2026.
Bonstein Sara sold 8.27K (~$961.04K) on May 13, 2026.
Adsett Roger sold 5.84K (~$678.14K) on May 13, 2026.
Flammer Martina M.D. sold 4.47K (~$504.04K) on May 13, 2026.
Flammer Martina M.D. sold 3.38K (~$393.15K) on May 13, 2026.

Latest INSM News

Insmed Target Cut to $185 Signals 58.7% Upside Despite 23% Q1 Revenue Miss — May 13, 2026
Insmed slides after May 7 Q1 results show revenue miss despite reiterated guidance — May 7, 2026
Insmed Q1 Revenues Reach $306M with 44% BRINSUPRI Surge and TPIP Progress — May 7, 2026
Insmed and Ty Pennington Launch Suspect Bronchiectasis Campaign for 500,000 Patients — May 6, 2026
Insmed rises ahead of May 7 Q1 results, as pre-earnings positioning builds — May 4, 2026

INSM Analyst Consensus

16 analysts cover INSM: 0 strong buy, 16 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $203.20.

Common questions about INSM

Who is trading INSM stock inside the company?: Recent INSM insider activity includes Flammer Martina M.D. sold 10.48K, Bonstein Sara sold 8.27K, Adsett Roger sold 5.84K, Flammer Martina M.D. sold 4.47K, and Flammer Martina M.D. sold 3.38K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for INSM?: Yes. Rallies tracks INSM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is INSM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for INSM. It does not provide personalized investment advice.